- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05453682
Hypofractionated IMRT With Concurrent Chemotherapy in Muscle-invasive Bladder Cancer (HIRACUM) (HIRACOM)
Hypofractionated Intensity-modulated Radiation Therapy With Concurrent Chemotherapy in Musc Le-invasive Bladder Cancer:
The purpose of this study is to investigate the side effects, quality of life, and treatment effects of concurrent chemo-hypofractionated intensity-modulated radiation therapy in bladder cancer.
Twenty fractionation within 4 weeks are performed using hypofractionated intensity-modulated radiation therapy. As for the radiation dose, 2.8-3.2 Gy at a time, total dose 56-64 Gy, to the high-risk target volume, and 2-2.2 Gy at a time, and 40-44 Gy, respectively, to the low-risk target volume. It aims to include more than 97% of the total dose to cover the entire PTV, and the minimum dose in the PTV is not lower than 95% of the prescribed dose, and the maximum dose does not exceed 107% of the prescribed dose. Chemotherapy before and after radiotherapy can be performed depending on the institutional policy. Among radiotherapy, chemotherapy is performed with platinum-based agents (cisplatin, carboplatin, etc.), and is administered once a week for a total of 3 or more.
Study Overview
Detailed Description
For bladder cancer, conventional concurrent chemoradiotherapy is irradiated with a daily radiation dose of 1.8-2.0 Gy each, a total of 64 Gy or more, and the radiation treatment period takes more than 6 weeks in bladder preserving protocol. Concurrent chemoradiotherapy has the advantage of bladder preservation, but gastrointestinal, genitourinary, and hematologic side effects occur in about 5%. Hypofractionated radiotherapy has the advantage of increasing the radiation-biological effect on tumors by reducing the number of treatments instead of increasing the daily dose, and shortening the overall treatment time. On the other hand, hypofractionated radiotherapy can also increase the risk of side effects related to treatment because the radiologic effects on normal tissues also increase. However, the biological effect of radiation on normal tissues can be reduced by applying intensity-modulated radiation therapy in hypofractional radiation therapy to reduce radiation exposure to normal tissues. Clinical studies of concurrent chemotherapy with hypofractionation radiation therapy are still in its insignificant stage.
The purpose of this study is to investigate the side effects, quality of life, and treatment effects of concurrent chemo-hypofractionated intensity-modulated radiation therapy in bladder cancer.
The 2-year bladder conserving disease-free survival rate after the existing concurrent chemo-radiation therapy is known to be about 55%, and when concurrent chemo-hyofractionated intensity-modulated radiation therapy is performed in invasive bladder cancer, the 2-year bladder conservation disease-free survival rate is expected about 70%. The number of patients required to verify this was 80% power, a significance level of alpha = 0.1, recruitment of patients for 3 years, and taking into account the follow-up observation for 2 years after recruitment, and setting the dropout rate of 15%, a total of 53 patients was necessary.
Twenty fractionation within 4 weeks are performed using hypofractionated intensity-modulated radiation therapy. As for the radiation dose, 2.8-3.2 Gy at a time, total dose 56-64 Gy, to the high-risk target volume, and 2-2.2 Gy at a time, and 40-44 Gy, respectively, to the low-risk target volume. It aims to include more than 97% of the total dose to cover the entire PTV, and the minimum dose in the PTV is not lower than 95% of the prescribed dose, and the maximum dose does not exceed 107% of the prescribed dose. Chemotherapy before and after radiotherapy can be performed depending on the institutional policy. Among radiotherapy, chemotherapy is performed with platinum-based agents (cisplatin, carboplatin, etc.), and is administered once a week for a total of 3 or more.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Won Park, Dr
- Phone Number: 82-10-9933-2616
- Email: wonro.park@samsung.com
Study Locations
-
-
-
Seoul, Korea, Republic of, 06351
- Recruiting
- Samsung Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients diagnosed with bladder cancer histologically
- Patients with muscle layer involvement in transurethral resection (pT2 or higher)
- Patients without pelvic lymph node metastasis by computed tomography (CT) or magnetic resonance images (MRI) of the pelvis.
- Patients who want bladder conservation treatment
- Patients over 20 years old
- Patients with Zubrod (ECOG) performance status 0-1 within 1 week prior to participation in the study
- Patients who have signed the consent form with sufficient information by the patient or guardian
- Patients with hematologic findings capable of concurrent chemoradiotherapy
Exclusion Criteria:
- Patients with previous pelvic radiotherapy history
- Pregnant or lactating patients
- Patients with distant metastasis
- Patients judged to be difficult to conserve bladder due to extensive non-invasive/invasive bladder cancer
- Patients who have not been disease-free for more than 5 years after diagnosis of cancer (excluding thyroid cancer, non-melanoma skin cancer, T1a prostate cancer, and intraepithelial cancer of the cervix)
- Patients with untreated severe acute disease
- Patients predicted to have a high probability of radiation complications due to connective tissue disease (lupus, scleroderma, etc.)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Hypo IMRT
in muscle invasive bladder cancer, hypofractionated IMRT with chemotherapy
|
Twenty fractionation within 4 weeks are performed using hypofractionated intensity-modulated radiation therapy.
As for the radiation dose, 2.8-3.2
Gy at a time, total dose 56-64 Gy, to the high-risk target volume, and 2-2.2 Gy at a time, and 40-44 Gy, respectively, to the low-risk target volume.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
bladder preservation disease-free survival rate
Time Frame: 2 years after participation of all subjects
|
Two-year bladder preservation disease-free survival rate when concurrent chemo-hypofractionated intensity-modulated radiation therapy
|
2 years after participation of all subjects
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of participants with treatment-related adverse events as assessed by Number of participants with treatment-related adverse events as assessed CTCAE v5.0 radiation therapy
Time Frame: 3 months after participation
|
acute toxicity
|
3 months after participation
|
Number of participants with treatment-related adverse events as assessed by CTCAE v5.0radiation therapy
Time Frame: 5 years after participation
|
late toxicity
|
5 years after participation
|
EORTC QOL-C30 measurement
Time Frame: 5 years after participation
|
QoL
|
5 years after participation
|
2 year disease-free survival when concurrent chemo-hypofractionated intensity-modulated radiation therapy
Time Frame: 2 years after participation of all subjects
|
disease-free survival
|
2 years after participation of all subjects
|
overall survival when concurrent chemo-hypofractionated intensity-modulated radiation therapy
Time Frame: 5 years after participation of all subjects
|
overall survival
|
5 years after participation of all subjects
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SMC-2021-01-026
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bladder Cancer
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedStage III Bladder Cancer | No Evidence of Disease | Stage II Bladder Cancer | Stage IVA Bladder Cancer | Stage IVB Bladder CancerUnited States
-
H. Lee Moffitt Cancer Center and Research InstituteCompletedMuscle-Invasive Bladder Carcinoma | Bladder Cancer Stage II | Bladder Cancer Stage III | Bladder Cancer Stage IVUnited States
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)WithdrawnRecurrent Bladder Cancer | Urinary Complications | Stage 0 Bladder Cancer | Stage I Bladder Cancer | Stage II Bladder Cancer
-
National Cancer Institute (NCI)CompletedStage III Bladder Cancer | Stage I Bladder Cancer | Stage II Bladder CancerUnited States
-
Fox Chase Cancer CenterTerminatedStage III Bladder Cancer | Distal Urethral Cancer | Proximal Urethral Cancer | Squamous Cell Carcinoma of the Bladder | Urethral Cancer Associated With Invasive Bladder Cancer | Stage II Bladder CancerUnited States
-
National Cancer Institute (NCI)TerminatedStage III Bladder Cancer | Stage IV Bladder Cancer | Recurrent Bladder Carcinoma | Bladder Adenocarcinoma | Bladder Squamous Cell Carcinoma | Bladder Urothelial Carcinoma | Stage I Bladder Cancer | Stage II Bladder CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedStage III Bladder Cancer | Stage IV Bladder Cancer | Recurrent Bladder Carcinoma | Stage II Bladder CancerUnited States
-
Academisch Medisch Centrum - Universiteit van Amsterdam...Bristol-Myers SquibbRecruitingUrinary Bladder Cancer | Invasive Bladder CancerNetherlands
-
Taris Biomedical LLCBristol-Myers SquibbTerminatedBladder Cancer TNM Staging Primary Tumor (T) T2 | Bladder Cancer TNM Staging Primary Tumor (T) T2A | Bladder Cancer TNM Staging Primary Tumor (T) T2B | Bladder Cancer TNM Staging Primary Tumor (T) T3 | Bladder Cancer TNM Staging Primary Tumor (T) T3A | Bladder Cancer TNM Staging Primary Tumor... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Bladder Cancer | Stage III Bladder Cancer | Stage IV Bladder Cancer | Transitional Cell Carcinoma of the Bladder | Stage I Bladder Cancer | Stage II Bladder CancerUnited States
Clinical Trials on hypo-IMRT
-
IRCCS Azienda Ospedaliero-Universitaria di BolognaUniversity of Bologna; Catholic University of the Sacred Heart; Howard UniversityCompletedProstate Cancer
-
Tata Memorial CentreTata Medical CenterRecruitingProstate AdenocarcinomaIndia
-
Novindiet ClinicTehran University of Medical Sciences; University of NottinghamCompletedObesity | OverweightIran, Islamic Republic of
-
Umeå UniversityRecruitingProstate Cancer | Metastatic Cancer | Radiotherapy Side EffectSweden
-
Centre for Contact Lens ResearchCoopervision, Inc.CompletedContact Lens Related Dry EyeCanada
-
Vanderbilt-Ingram Cancer CenterRecruitingSoft Tissue SarcomasUnited States
-
Society for Applied StudiesCompleted
-
International Centre for Diarrhoeal Disease Research...United States Agency for International Development (USAID)Completed
-
UMC UtrechtRadboud University Medical Center; Universitaire Ziekenhuizen KU Leuven; The...CompletedProstate Cancer AdenocarcinomaNetherlands, Belgium
-
Stanford UniversityCompletedProstatic NeoplasmsUnited States